Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Rosa Anna Passerotto; Francesco Lamanna; Damiano Farinacci; Alex Dusina; Simona Di Giambenedetto; Arturo Ciccullo; Alberto Borghetti

doi:10.1016/j.imj.2023.02.004

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report

Infect Med (Beijing). 2023 Jun;2(2):143-147. doi: 10.1016/j.imj.2023.02.004. Epub 2023 Mar 4.

Authors

Rosa Anna Passerotto¹, Francesco Lamanna¹, Damiano Farinacci¹, Alex Dusina², Simona Di Giambenedetto^{1

2}, Arturo Ciccullo³, Alberto Borghetti²

Affiliations

¹ Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
² Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
³ Infectious Diseases Unit, San Salvatore Hospital, 67100 L'Aquila, Italy.

Abstract

We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation, not vaccinated for SARS-COV-2, hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit (ICU). The hospitalization was complicated by bacteraemic ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) isolated on pleural fluid culture, treated with colistin and cefiderocol for about 3 weeks. The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy. The aim is to show the safety, efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.

Keywords: Acinetobacter baumannii; HIV; SARS-CoV-2; cefiderocol; colistin.

Publication types

Case Reports